The Texas Department of Licensing and Regulation announced on Monday that UFC women’s bantamweight fighter Jessica Eye tested positive for a banned drug in her UFC 166 drug test and her bout with Sarah Kaufmann has been overturned to a no decision.
Eye received a probated suspension and a fine for testing positive for a prohibited drug. The probated suspension is a warning and Eye is allowed to continue to take fights right now.
On Wednesday evening, the UFC released a statement on the situation, which they intend to honor the probation handed down by the Texas Department of Licensing and Regulation and Eye’s scheduled bout with Alexis Davis will remain on the UFC 170 card.
“The UFC received word of the fully probated suspension and fine issued to Jessica Eye by the Texas Department of Licensing and Regulation,” the UFC statement said. “The UFC intends to honor the probation, which will not force Eye to miss her scheduled bout at UFC 170.”
Along with the UFC releasing a statement, Eye made her first comments on the situation and she has accepted the terms of the probation handed down by the Texas Department of Licensing and Regulation.
“I was recently alerted to the fact that I was issued a fully probated suspension and fine by the Texas Department of Licensing and Regulation,” Eye said in a statement. “While I intend to discuss with the Texas Department of Licensing and Regulation the overturning of my victory at UFC 166, I have accepted the terms of the probation and intend to compete at UFC 170 on Feb. 22. I pride myself on following the rules and representing my family, teammates, sponsors, and fans in the best light possible. I apologize for any distractions this has caused.”
Eye and Davis are scheduled to be the feature preliminary bout on the UFC 170 card on February 22nd in Las Vegas, which will air live on Fox Sports 1. With the lightweight bout between Rustam Khabilov and Rafael dos Anjos being pulled from the card, the bout between Eye and Davis could end up being elevated to the main card on pay-per-view.